[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX9303612A - Composiciones estables de microgranulos de omepr azol gastroprotegidos y su procedimiento de obtencion. - Google Patents

Composiciones estables de microgranulos de omepr azol gastroprotegidos y su procedimiento de obtencion.

Info

Publication number
MX9303612A
MX9303612A MX9303612A MX9303612A MX9303612A MX 9303612 A MX9303612 A MX 9303612A MX 9303612 A MX9303612 A MX 9303612A MX 9303612 A MX9303612 A MX 9303612A MX 9303612 A MX9303612 A MX 9303612A
Authority
MX
Mexico
Prior art keywords
microgranules
omepr
gastroproteged
azol
procedure
Prior art date
Application number
MX9303612A
Other languages
English (en)
Inventor
Patrice Debregeas
Gerard Leduc
Original Assignee
Ethypharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9430771&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9303612(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ethypharm Sa filed Critical Ethypharm Sa
Publication of MX9303612A publication Critical patent/MX9303612A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Epoxy Resins (AREA)

Abstract

La invención consiste en aplicar una dilución seca de cantidades sensiblemente comparables de omeprazol y mannitol sobre granos neutros, proteger los granos activo obtenidos por este medio con mannitol, y a continuación volverlos gastroprotegidos. Los microgránulos protegidos por este medio presentan una estabilidad considerable.
MX9303612A 1992-06-16 1993-06-16 Composiciones estables de microgranulos de omepr azol gastroprotegidos y su procedimiento de obtencion. MX9303612A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9207249A FR2692146B1 (fr) 1992-06-16 1992-06-16 Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.

Publications (1)

Publication Number Publication Date
MX9303612A true MX9303612A (es) 1994-04-29

Family

ID=9430771

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9303612A MX9303612A (es) 1992-06-16 1993-06-16 Composiciones estables de microgranulos de omepr azol gastroprotegidos y su procedimiento de obtencion.

Country Status (25)

Country Link
US (1) US5385739A (es)
EP (1) EP0646006B1 (es)
JP (1) JP3568950B2 (es)
KR (1) KR100193966B1 (es)
CN (1) CN1051225C (es)
AT (1) ATE149835T1 (es)
AU (1) AU669719B2 (es)
CA (1) CA2138149C (es)
CZ (1) CZ287260B6 (es)
DE (1) DE69308849T2 (es)
DK (1) DK0646006T3 (es)
ES (1) ES2052458B1 (es)
FI (1) FI111220B (es)
FR (1) FR2692146B1 (es)
GE (1) GEP20002015B (es)
GR (2) GR1001535B (es)
MD (1) MD1472G2 (es)
MX (1) MX9303612A (es)
NZ (1) NZ253179A (es)
PL (1) PL172706B1 (es)
RU (1) RU2103995C1 (es)
SK (1) SK280198B6 (es)
TJ (1) TJ230B (es)
WO (1) WO1993025204A1 (es)
ZA (1) ZA934266B (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426085B1 (en) 1994-05-02 2002-07-30 Josman Laboratories Inc. Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
US5834002A (en) 1994-05-02 1998-11-10 Josman Laboratories, Inc. Chewing gum containing colloidal bismuth subcitrate
US6902738B2 (en) * 1994-05-02 2005-06-07 Josman Laboratories, Inc. Topical oral dosage forms containing bismuth compounds
ES2087823B1 (es) * 1994-07-13 1997-02-16 Estudes Et Richerches Pharma E Formulacion de microgranulos gastroresistentes de omeprazol y su procedimiento de fabricacion.
JP3743519B2 (ja) * 1994-10-18 2006-02-08 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ シリコン−酸化物薄層の製造方法
ES2094694B1 (es) 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
US6372784B1 (en) 1995-02-07 2002-04-16 Josman Laboratories, Inc. Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
US6379651B1 (en) 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
WO1996024341A1 (en) * 1995-02-07 1996-08-15 Narayan Krishnarao Athanikar Concomitant treatment with bismuth and antibacterials
US5547844A (en) * 1995-02-23 1996-08-20 The Regents Of The University Of California Helicobacter pylori bacterial derived factor
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
ES2220989T3 (es) * 1995-09-21 2004-12-16 Pharma Pass Ii Llc Nueva composicion que contiene benzimidazol labil al acido y procedimiento para su preparacion.
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
CO4771151A1 (es) * 1996-01-19 1999-04-30 Rachitzky Falicman Pablo Alberto Procedimiento para la elaboracion de una preparacion farmace utica que contiene nifedipina y la preparacion farmaceutica obtenida mediante el mismo
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
FR2771291B1 (fr) * 1997-11-21 2000-02-25 Ethypharm Lab Prod Ethiques Spheroides, procede de preparation et compositions pharmaceutiques
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
DK1105105T3 (da) * 1998-08-12 2006-07-17 Altana Pharma Ag Oral administrationsform til pyridin-2-ylmethylsulfinyl-1H-benzimidazoler
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
KR100314351B1 (ko) * 1998-10-01 2002-03-21 민경윤 벤즈이미다졸유도체의장용성제제및그제조방법
FR2790668B1 (fr) * 1999-03-12 2002-07-26 D B F Granules contenant une substance vegetale et leur procede de preparation
FR2793688B1 (fr) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
IL130602A0 (en) 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6780880B1 (en) * 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6228400B1 (en) 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
GB9923436D0 (en) * 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
DE19959419A1 (de) 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
ATE297194T1 (de) * 1999-12-16 2005-06-15 Medinfar Produtos Farmaceutico Neue stabile mehreinheitliche substituierte benzimidazole enthaltende pharmazeutische präparate
US6346269B1 (en) * 2000-05-08 2002-02-12 Standard Chem. & Pharm. Co., Ltd. Method for preparing an oral formulation containing acid-sensitive drugs and oral formulation made thereby
DE10033023A1 (de) * 2000-07-07 2002-01-31 Biogrund Gmbh Filmüberzugszusammensetzung auf Basis von Zellulosederivaten und Zuckeralkoholen
US6749867B2 (en) * 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
ES2192929B1 (es) * 2001-04-06 2005-02-16 Laboratorios Belmac, S.A. Procedimiento mejorado para la obtencion de pellets de omeprazol estables y gastrorresistentes, pellets asi obtenidos y aplicaciones.
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
CA2472103A1 (en) * 2002-01-25 2003-08-07 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
ATE363480T1 (de) * 2002-03-05 2007-06-15 Astrazeneca Ab Alkylammoniumsalze von omeprazol und esomeprazol
PT1524967E (pt) * 2002-08-02 2008-04-03 Ratiopharm Gmbh Preparação farmacêutica contendo um composto de benzimidazole misturado com celulose microcristalina e método para a sua preparação.
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
US20050191353A1 (en) * 2002-08-16 2005-09-01 Amit Krishna Antarkar Process for manufacture of stable oral multiple unit pharmaceutical composition containing benzimidazoles
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
WO2004066982A1 (en) * 2003-01-31 2004-08-12 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and processes for their preparation
WO2004073654A2 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained supression of gastric acid
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
MXPA06000529A (es) * 2003-07-18 2006-08-11 Santarus Inc Formulaciones farmaceuticas utiles para inhibir la secrecion de acido y metodos para elaborarlas y utilizarlas.
CA2531566C (en) * 2003-07-18 2013-05-07 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
CN1874764B (zh) 2003-10-10 2012-08-01 埃法尔姆公司 含有银杏提取物的持续释放微粒及其制备方法
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
EP1720527A2 (en) * 2004-03-03 2006-11-15 Teva Pharmaceutical Industries Ltd A stable pharmaceutical composition comprising an acid labile drug
CN1938026A (zh) * 2004-03-26 2007-03-28 卫材R&D管理有限公司 控释制剂及其制造方法
SI1746980T1 (sl) * 2004-05-07 2012-03-30 Nycomed Gmbh Farmacevtska dozirna oblika ki obsega pelete kot tudi postopek za njeno pripravo
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1830823A2 (en) 2004-12-23 2007-09-12 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
AU2006213439A1 (en) * 2005-01-03 2006-08-17 Lupin Limited Pharmaceutical composition of acid labile substances
WO2006087613A2 (en) * 2005-02-02 2006-08-24 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions prepared by non-aqueous layering process
EP1930030A1 (en) * 2005-09-29 2008-06-11 Eisai R&D Management Co., Ltd. Pulse preparation having improved disintegration properties in vivo
EP1785135A1 (en) 2005-11-10 2007-05-16 Laboratorios Del Dr. Esteve, S.A. New stabilized galenic formulations comprising lansoprazole and their preparation
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
AU2007205893A1 (en) * 2006-01-19 2007-07-26 The Curators Of The University Of Missouri Pharmaceutical composition comprising a protein pump inhibitor and protein component
AU2007266574A1 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008062320A2 (en) * 2006-10-06 2008-05-29 Eisai R&D Management Co., Ltd Extended release formulations of a proton pump inhibitor
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
FR2943546A1 (fr) * 2009-03-31 2010-10-01 Nouveaux Produits Pharma Sas Excipient pharmaceutique fonctionnalise ameliorant la biodisponibilite de substances actives peu solubles, microgranules l'incorporant.
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
KR101787481B1 (ko) 2010-10-21 2017-10-18 롯데정밀화학 주식회사 장용성 경질 캡슐용 조성물 및 상기 조성물을 사용하여 제조된 장용성 경질 캡슐
PL2773348T3 (pl) 2011-11-02 2018-07-31 Laboratorios Del. Dr. Esteve, S.A. Kompozycja farmaceutyczna omeprazolu
WO2013122553A1 (en) * 2012-02-14 2013-08-22 Mahmut Bilgic A pharmaceutical formulation comprising an atp-ase inhibitor and method for this formulation
WO2013122554A1 (en) * 2012-02-14 2013-08-22 Mahmut Bilgic Pellet formulations comprising esomeprazole
KR101340733B1 (ko) * 2012-12-31 2013-12-12 (주) 에프엔지리서치 신규한 마이크로그래뉼 제형
WO2016174664A1 (en) * 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3292862A1 (en) 2016-09-07 2018-03-14 Sandoz Ag Omeprazole formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
IT1215726B (it) * 1988-01-18 1990-02-22 Alfa Wassermann Spa Formulazioni galeniche a cessione programmata.
US5188836A (en) * 1990-07-27 1993-02-23 Warner-Lambert Company Sustained release formulations
ES2024993A6 (es) * 1990-12-31 1992-03-01 Genesis Para La Investigacion Procedimiento de obtencion de un preparado farmaceutico oral conteniendo omeprazol.

Also Published As

Publication number Publication date
MD960332A (en) 1998-03-31
MD1472G2 (ro) 2001-01-31
CA2138149A1 (fr) 1993-12-23
FI945904A (fi) 1994-12-15
CZ287260B6 (en) 2000-10-11
GR3023391T3 (en) 1997-08-29
WO1993025204A1 (fr) 1993-12-23
TJ230B (en) 1999-11-24
ATE149835T1 (de) 1997-03-15
SK280198B6 (sk) 1999-09-10
DE69308849D1 (de) 1997-04-17
FI111220B (fi) 2003-06-30
JP3568950B2 (ja) 2004-09-22
EP0646006A1 (fr) 1995-04-05
CZ316594A3 (en) 1995-05-17
GR1001535B (el) 1994-03-31
DE69308849T2 (de) 1997-09-04
RU2103995C1 (ru) 1998-02-10
ES2052458A1 (es) 1994-07-01
FR2692146B1 (fr) 1995-06-02
ES2052458B1 (es) 1995-01-16
NZ253179A (en) 1996-05-28
KR100193966B1 (ko) 1999-06-15
ZA934266B (en) 1996-02-09
GEP20002015B (en) 2000-04-10
PL172706B1 (en) 1997-11-28
KR940000106A (ko) 1994-01-03
EP0646006B1 (fr) 1997-03-12
CA2138149C (fr) 2003-08-19
JPH07508509A (ja) 1995-09-21
CN1051225C (zh) 2000-04-12
MD1472F2 (en) 2000-05-31
DK0646006T3 (da) 1997-10-13
CN1086130A (zh) 1994-05-04
FR2692146A1 (fr) 1993-12-17
SK155194A3 (en) 1997-01-08
RU94046268A (ru) 1996-10-10
FI945904A0 (fi) 1994-12-15
AU4332193A (en) 1994-01-04
US5385739A (en) 1995-01-31
AU669719B2 (en) 1996-06-20

Similar Documents

Publication Publication Date Title
MX9303612A (es) Composiciones estables de microgranulos de omepr azol gastroprotegidos y su procedimiento de obtencion.
HUT45844A (en) Pesticides comprising imidazole derivatives as active ingredient and process for producing the active ingredients
HUP0002364A2 (hu) Savérzékeny benzimidazolok stabilizálása aminosav-ciklodextrin kombinációkkal
HU178663B (en) Fungicide compositions containing cyanopirrole derivatives as active agents,and process for producing the active agents
PL268927A1 (en) Method of obtaining novel derivatives of benzimidazole
HUT37745A (en) Pesticide, first of all insecticide compositions containing substituted malonic acid derivatives as active agents and process for producing substituted malonic acid derivatives
AU536920B2 (en) Hydroxypropyl-triazole derivatives and their use as antimycotic agents
NO164473C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 2-pyridylmethyl-thio- og -sulfinylbenzimidazoler.
DK495884A (da) Shellakindkapslingsmiddel til aktive bestanddele i tyggegummi
DK1333812T3 (da) Mikrogranulat baseret på aktivt stof og fremgangsmåde til at fremstille samme
HUT48216A (en) Insecticidal, nematocidal, coccidiostatic compositions comprising n-phenylpyrazole derivatives and process for producing the active ingredients
HU185766B (en) Process for producing 1-bracket-2-aryl-1,3-dioxan-2-yl-methyl-bracket closed-1h-imidazol and -1h-1,2,4-triazol derivatives and fungicide compositions containing them as active agents
IT8019711A0 (it) Composizioni da usarsi come cosmetici e procedimento per lapreparazione dei loro ingredienti attivi.
IT8324430A0 (it) Attivita' antitosse e sedativa composti otticamente attivi ad centrale, procedimento per la loro preparazione e composizioni che licontengono.
HUT47124A (en) Process for producing pharmaceutical compositions comprising organic platinum complex as active ingredient and the active ingredients
ATE236621T1 (de) Niedrig dosierte tabletten, und verfahren zur herstellung
HUT41376A (en) Insecticide compositions containing phenyl-hidrazine derivatives as active agents and process for producing the active agents
NO160442C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive pyrazolo (1,5-a)pyridinderivater.
HUT55954A (en) Fungicidal compositions comprising 3-substituted pyridine as active ingredient and process for producing the active ingredients
EP0056681A3 (en) Levonantradol and n-methyllevonantradol formulations
IT7948907A0 (it) Derivati di 1,3 benzodiossina procedimento per la loro produzione e composizioni farmaceutiche che licontengono come ingredienti attivi
JPS5379030A (en) Dungicide composition for agriculture and horticulture
IT1162386B (it) Perfezionamento negli esteri fosforici organici utili in composizioni insetticide acaricide e nematocide e procedimento per la loro preparazione
IT7829164A0 (it) Aril-alchil-piperazine farmaceuticamente attive, procedimenti per la loro preparazione e composizioni relative.
IT1114485B (it) Derivati dell'idantoina procedimento per la loro produzione e composizioni che li contengono come ingrediente attivo

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights
PD Change of proprietorship

Owner name: ETHYPHARM

MM Annulment or lapse due to non-payment of fees